Search results for Daclizumab

Daclizumab Biosimilar – Anti-IL2RA mAb – Research Grade, ProteoGenix, PX-TA1038

Description of Daclizumab Biosimilar - Anti-IL2RA mAb - Research Grade General information on Anti-IL2RA(Homo sapiens) (Daclizumab) Monoclonal Antibody Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.

Daclizumab, Kyinno, KB-1313

Daclizumab, Abbexa, abx831005

Daclizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL2RA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) 2. Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016.

Daclizumab ELISA Kit, ProteoGenix, KPTX135

Description of Daclizumab ELISA Kit Introduction to Daclizumab ELISA Kit Daclizumab ELISA Kit is an advanced diagnostic tool used for the detection and quantification of Daclizumab, a humanized monoclonal antibody. This kit is specifically designed for the accurate measurement of Daclizumab levels in biological samples such as serum, plasma, and tissue culture supernatants. Daclizumab is a therapeutic antibody that targets the interleukin-2 receptor (IL-2R) and is used in the treatment of multiple sclerosis (MS). In this article, we will discuss the structure, activity, and application of Daclizumab ELISA Kit in detail. Structure of Daclizumab Daclizumab is a recombinant humanized IgG1 monoclonal antibody that is produced by recombinant DNA technology. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of Daclizumab binds to the IL-2R, while the constant region mediates the effector functions of the antibody. Activity of Daclizumab Daclizumab acts as an immunosuppressive agent by targeting the IL-2R, which is expressed on the surface of activated T cells. IL-2R is a key receptor involved in the activation and proliferation of T cells. By binding to the IL-2R, Daclizumab prevents the binding of interleukin-2 (IL-2), a cytokine that promotes T cell growth and survival. This leads to a decrease in the number of activated T cells and ultimately reduces the immune response. Application of Daclizumab ELISA Kit The Daclizumab ELISA Kit is an essential tool for monitoring Daclizumab levels in patients undergoing treatment for MS. It is used in clinical trials to evaluate the pharmacokinetics and pharmacodynamics of Daclizumab and to determine the appropriate dosage for patients. The kit is also used in routine clinical practice to assess the response to treatment and to adjust the dosage accordingly. Measurement of Daclizumab Levels The Daclizumab ELISA Kit utilizes a sandwich enzyme-linked immunosorbent assay (ELISA) technique for the quantitative measurement of Daclizumab in biological samples. The assay involves the use of two specific antibodies that recognize different epitopes on the Daclizumab molecule. The first antibody is coated on the surface of the microplate, and the sample containing Daclizumab is added. The Daclizumab in the sample binds to the first antibody, forming a complex. The second antibody, which is conjugated to an enzyme, is then added, and it binds to the other end of the Daclizumab molecule, forming a sandwich complex. The amount of Daclizumab present in the sample is directly proportional to the color intensity produced by the enzyme substrate reaction. The absorbance is then measured using a microplate reader, and the Daclizumab concentration is determined by comparing it to a standard curve. Advantages of Daclizumab ELISA Kit The Daclizumab ELISA Kit offers several advantages over other methods of Daclizumab detection. It is a highly sensitive and specific assay, with a detection limit of 0.1 ng/mL. It is also a rapid and cost-effective method, with results available within a few hours. The kit is compatible with a wide range of biological samples and has been validated for use in serum, plasma, and tissue culture supernatants. It also has a high throughput capacity, allowing for the analysis of multiple samples simultaneously. Clinical Significance of Daclizumab ELISA Kit The Daclizumab ELISA Kit has significant clinical implications in the treatment of MS. It allows for the accurate monitoring of Daclizumab

Daclizumab ELISA Kit, Abbexa, abx395024

Daclizumab ELISA Kit is a quantitative ELISA kit for detection of Daclizumab.Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T cell activation, regulatory T cell expansion and survival, and activation-induced T-cell apoptosis. Because CD25 blockade reduces IL-2 consumption by effector T cells, it increases IL-2 bioavailability allowing for greater interaction with the intermediate-affinity IL-2R, and therefore drives the expansion of CD56bright natural killer (NK) cells. Furthermore, there appears to be a direct correlation between CD56bright NK cell expansion and DAC HYP efficacy in reducing relapses and MRI evidence of disease activity in patients with RMS in phase II and phase III double-blind, placebo- and active comparator-controlled trials. Therapeutic efficacy was maintained during open-label extension studies. However, treatment was associated with an increased risk of rare adverse events, including cutaneous inflammation, autoimmune hepatitis, central nervous system Drug Reaction with Eosinophilia Systemic Symptoms (DRESS) syndrome, and autoimmune Glial Fibrillary Acidic Protein (GFAP) alpha immunoglobulin-associated encephalitis. As a result, DAC HYP was removed from clinical use in 2018. The lingering importance of DAC is that its use led to a deeper understanding of the underappreciated role of innate immunity in the potential treatment of autoimmune disease.

Daclizumab Biosimilar - Research Grade, ichor.bio, ICH5021

Detects human CD25. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Daclizumab.

Research Grade Daclizumab (HF996016), abinScience, HF996016